Datamonitor's October
edition of the IDI Review brings you the latest news, analysis and
research covering immune disorders and inflammation.
It covers all the major current business
issues and events, including R&D, licensing deals, alliances and joint
ventures, and regulatory decisions.
Scope
-
Strategic insight into the future shape
of IDI companies and markets
-
The most significant IDI industry news
compiled into one monthly update
-
Expert analysis into the implications
of the month's important IDI industry events
-
Insight into the future shape of the
market for players at all levels
-
All the month's IDI stories in headline
and summary form
Report Highlights
Out of the dozens of topics covered in this
month's review, the most important include:
* Roche released the results of the
four-year landmark Xendos study involving 3,304 patients which
demonstrated that the weight loss medication Xenical can significantly
prevent or delay the development of type 2 diabetes.
* Bayer has filed for approval for its
immune globulin intravenous drug, Gamunex. It's a purer alternative to
Bayer's existing Gamimune; its major indication is primary
immunodeficiency.
Reasons to Purchase
-
Not only keeps you updated about
industry events - it also gives you opinion and insight
-
Draws upon Datamonitor analysts'
extensive experience to bring you our perspective on the impact of the
latest events
-
Provides you with your own news archive
to track company and industry progress, giving you an extensive
reference to relevant events and issues
R&D UPDATE: EPHARMA
The most significant news
in ePharma R&D, compiled into one monthly update.
R&D UPDATE: EPYHSICIAN
The most significant news
in ePhysician R&D, compiled into one monthly update.
FEATURE ANALYSIS
Analyst-written feature
articles, featuring the latest insights into the industry
-
ePharma: targeting the online health
conscious
NEWS HEADLINES - EPHARMA
All the month's ePharma
news stories in headline and summary form
NEWS HEADLINES - EPYHSICIAN
All the month's ePhysician
news stories in headline and summary form
To
order - click here!
